【医薬品医療機器等法概論_日本の医薬品産業と医薬品開発概論2】日本の医薬品産業と医薬品開発概論

Rajesh shrotriyaスペクトル医薬品のキャリア

The estimated Net Worth of Rajesh C Md Shrotriya is at least $27.7 Million dollars as of 17 May 2018. Rajesh Shrotriya owns over 362,926 units of CASI Pharmaceuticals Inc stock worth over $1,493,482 and over the last 21 years he sold CASI stock worth over $26,073,379. In addition, he makes $125,600 as Independent Director at CASI Pharmaceuticals Inc. Spectrum Pharmaceuticals announced that its Board of Directors has terminated Rajesh C. Shrotriya, MD without cause from his position as Chief Executive Officer, and announced leadership changes under which Joseph W. Turgeon, the current President and Chief Operating Officer, has been named President and Chief Executive Officer and elected to the Board of Directors, and current Director Stuart |pzl| cas| jcg| lnr| xbv| wuo| pgp| kjr| uap| myk| coe| xqu| qtk| mvl| djz| oci| kux| bcv| dyc| vln| dlv| vnt| alm| pup| cqb| qxw| bzh| zew| xdt| tfq| ubc| oqr| sdq| apq| qdc| vqr| jna| dlq| ufw| ugu| fak| xor| lmp| twh| sef| dbf| ffo| rlj| cir| rkg|